Digital therapeutics in mental health: access, evidence, and what reimbursement looks like

What digital therapeutics in mental health are

Digital therapeutics (DTx) in mental health are software-based interventions, typically grounded in cognitive-behavioural therapy or a related evidence-based psychotherapy modality, delivered through smartphone apps or web platforms. They are distinguished from wellness apps by:

• FDA clearance (or equivalent in other regulatory frameworks) for specific indications
• Evidence base derived from randomised controlled trials
• Prescription requirement (in the US) or specific clinical-pathway integration (in other markets)
• Reimbursement pathway, typically through insurance or health-system commissioning

Indications with FDA-cleared DTx include treatment-resistant depression, generalised anxiety disorder, insomnia, substance use disorder, and pediatric ADHD.

The evidence base

The evidence base for the leading DTx products is built on RCTs comparing the digital intervention against active control (typically standard care or wait-list) on validated psychiatric symptom measures. Effect sizes have generally been in the small-to-moderate range, broadly comparable to the effect sizes for medication monotherapy in mild-to-moderate disease.

The methodological questions the field continues to address:

• Adherence is a substantial issue. Patient engagement with the intervention varies widely, and the trial-versus-real-world adherence gap is wider than for medication therapy
• Comparator choice. Active comparator trials (versus face-to-face CBT, versus medication) are less common than placebo-comparator trials, and the relative efficacy positioning is therefore uncertain
• Indication-specific evidence. The evidence base is stronger in depression, anxiety and insomnia than in adjacent indications

The access frame

Reimbursement pathways for mental health DTx are evolving:

• United States: FDA clearance enables prescribing; reimbursement pathways are evolving through specific CPT codes and through CMS engagement on Medicare coverage. Commercial coverage is variable
• Germany: The Digital Health Applications (DiGA) framework provides a defined reimbursement pathway for approved digital health applications, with mental health being a substantial portion of the approved DiGA portfolio
• United Kingdom: NICE engagement on digital therapeutics has been variable; specific DTx products have NHS commissioning in some regions
• Other markets: Varied and evolving, with most major markets still building the formal access architecture

What this means for commercial teams

For sponsors of mental health DTx and for sponsors of adjacent medication therapy:

• DTx and medication are increasingly part of the same treatment pathway, not competing categories. The treat-to-target frame in mental health (where it applies) often includes both
• The access architecture for DTx is more variable across markets than for medication, and commercial planning has to track each market separately
• The provider-engagement model is different from medication. Prescribers' familiarity with DTx is uneven, and the prescription-to-uptake conversion is harder than for medication therapy

What we are watching

• US reimbursement pathway evolution as Medicare and commercial payers settle coverage frames
• DiGA expansion in Germany and the regulatory frame's exportability to other European markets
• DTx-medication combination evidence as the field tests integrated care approaches